<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01351753</url>
  </required_header>
  <id_info>
    <org_study_id>201012738</org_study_id>
    <nct_id>NCT01351753</nct_id>
  </id_info>
  <brief_title>Drug Therapy Induced Weight Loss to Improve Blood Vessel Function in Subjects With Obesity</brief_title>
  <acronym>REVIVE</acronym>
  <official_title>Does Reversal of Visceral Obesity by Drug Therapy Improve Vascular Function?</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Iowa</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Iowa</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Obesity is common (&gt;30% of US adults), contributes to substantial morbidity and mortality,&#xD;
      but is difficult to treat. Partly this is due to the transient, arduous and modest nature of&#xD;
      lifestyle interventions. Partly it is due to the limited efficacy and safety problems of&#xD;
      existing pharmacotherapy. Only one drug, orlistat, is approved for long-term use in obesity;&#xD;
      but its effects on weight are relatively small. There are drugs that have been approved for&#xD;
      other diseases but which also reduce weight. One promising approach to treating obesity is&#xD;
      combination therapy with orlistat and one or more of these other agents. The investigators&#xD;
      propose an innovative approach to developing new therapies for obesity coupling the use of&#xD;
      combination therapy with rigorous assessment of cardiovascular safety. Vascular function is a&#xD;
      quantitative surrogate clinical endpoint that has been strongly and independently linked to&#xD;
      future cardiovascular events.&#xD;
&#xD;
      Our hypothesis is that combination pharmacotherapy will reduce weight and improve vascular&#xD;
      function in obese human subjects. The co-primary endpoints will be weight and vascular&#xD;
      function.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Lack of funding&#xD;
  </why_stopped>
  <start_date type="Actual">March 2011</start_date>
  <completion_date type="Actual">January 9, 2014</completion_date>
  <primary_completion_date type="Actual">January 9, 2014</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Weight (% Change From Baseline)</measure>
    <time_frame>6 months</time_frame>
    <description>Weight obtained in the fasting state on a gowned subject.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Office Systolic Blood Pressure (mmHg Change From Baseline)</measure>
    <time_frame>6 months</time_frame>
    <description>Automated sphygmomanometry while sitting</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Waist (cm Change After 6 Months From Baseline)</measure>
    <time_frame>6 months</time_frame>
    <description>Body fat distribution measured using anthropometry (waist, neck and hip circumferences)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Carotid-femoral Pulse Wave Velocity (PWV)(Change After 6 Months From Baseline)</measure>
    <time_frame>6 months</time_frame>
    <description>Change in carotid-femoral pulse wave velocity (Sphygmocor).</description>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Actual">136</enrollment>
  <condition>Obesity</condition>
  <condition>Metabolic Syndrome X</condition>
  <arm_group>
    <arm_group_label>Metformin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Metformin + Orlistat</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Metformin + Topiramate</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Topiramate</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Metformin + Topiramate + Orlistat</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Metformin</intervention_name>
    <arm_group_label>Metformin</arm_group_label>
    <arm_group_label>Metformin + Orlistat</arm_group_label>
    <arm_group_label>Metformin + Topiramate</arm_group_label>
    <arm_group_label>Metformin + Topiramate + Orlistat</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Orlistat</intervention_name>
    <arm_group_label>Metformin + Orlistat</arm_group_label>
    <arm_group_label>Metformin + Topiramate + Orlistat</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Topiramate</intervention_name>
    <arm_group_label>Metformin + Topiramate</arm_group_label>
    <arm_group_label>Metformin + Topiramate + Orlistat</arm_group_label>
    <arm_group_label>Topiramate</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo pills and capsules for metformin, orlistat and topiramate</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age 40 to 75 years&#xD;
&#xD;
          -  Male or postmenopausal female&#xD;
&#xD;
          -  BMI â‰¥ 30 kg/m2&#xD;
&#xD;
          -  One or more major cardiovascular (CV) risk factors (hypertension, dyslipidemia,&#xD;
             impaired glucose tolerance OR metabolic syndrome)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Congestive heart failure&#xD;
&#xD;
          -  Renal impairment&#xD;
&#xD;
          -  History of bariatric surgery (i.e. lap-band, Roux-en-Y or biliopancreatic diversion)&#xD;
&#xD;
          -  Type I diabetes mellitus&#xD;
&#xD;
          -  Weight loss &gt; 10% in the past 6 months&#xD;
&#xD;
          -  Recurrent nephrolithiasis&#xD;
&#xD;
          -  Current treatment for seizure disorder&#xD;
&#xD;
          -  Hepatic cirrhosis&#xD;
&#xD;
          -  Current use of study medications&#xD;
&#xD;
          -  Current use of oral estrogen&#xD;
&#xD;
          -  History of smoking cessation in the past three months&#xD;
&#xD;
          -  Current cholestasis or malabsorption syndrome&#xD;
&#xD;
          -  Planned use of any herbal or over-the-counter supplements for weight loss&#xD;
&#xD;
          -  History of allergic reactions to metformin, topiramate, orlistat or any of ingredients&#xD;
&#xD;
          -  Medical conditions requiring continuous use of phosphodiesterase inhibitors and/or the&#xD;
             inability to withhold phosphodiesterase inhibitors for 48 hours&#xD;
&#xD;
          -  Participation in another clinical drug study within four weeks prior to this&#xD;
             investigation.&#xD;
&#xD;
          -  Participation in any other weight loss or rigorous exercise program.&#xD;
&#xD;
          -  Any disease or condition that in the opinion of the investigator may interfere with&#xD;
             completion of the study&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gary L Pierce, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Iowa</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Iowa Hospitals and Clinics</name>
      <address>
        <city>Iowa City</city>
        <state>Iowa</state>
        <zip>52241</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://goo.gl/IHNtm</url>
    <description>Recruitment website</description>
  </link>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>May 4, 2011</study_first_submitted>
  <study_first_submitted_qc>May 9, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 11, 2011</study_first_posted>
  <results_first_submitted>May 13, 2021</results_first_submitted>
  <results_first_submitted_qc>May 13, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">June 9, 2021</results_first_posted>
  <last_update_submitted>May 13, 2021</last_update_submitted>
  <last_update_submitted_qc>May 13, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 9, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Iowa</investigator_affiliation>
    <investigator_full_name>Gary L. Pierce</investigator_full_name>
    <investigator_title>Associate Professor</investigator_title>
  </responsible_party>
  <keyword>Obesity</keyword>
  <keyword>Metabolic Syndrome X</keyword>
  <keyword>Hypertension</keyword>
  <keyword>Dyslipidemia</keyword>
  <keyword>Impaired glucose tolerance</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Microvascular Angina</mesh_term>
    <mesh_term>Obesity</mesh_term>
    <mesh_term>Metabolic Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Metformin</mesh_term>
    <mesh_term>Topiramate</mesh_term>
    <mesh_term>Orlistat</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Metformin</title>
          <description>Metformin only</description>
        </group>
        <group group_id="P2">
          <title>Metformin + Orlistat</title>
          <description>Metformin&#xD;
Orlistat</description>
        </group>
        <group group_id="P3">
          <title>Metformin + Topiramate</title>
          <description>Metformin&#xD;
Topiramate</description>
        </group>
        <group group_id="P4">
          <title>Topiramate</title>
          <description>Topiramate only</description>
        </group>
        <group group_id="P5">
          <title>Metformin + Topiramate + Orlistat</title>
          <description>Metformin&#xD;
Orlistat&#xD;
Topiramate</description>
        </group>
        <group group_id="P6">
          <title>Placebo</title>
          <description>Placebo: Placebo pills and capsules for metformin, orlistat and topiramate</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="22"/>
                <participants group_id="P2" count="20"/>
                <participants group_id="P3" count="21"/>
                <participants group_id="P4" count="21"/>
                <participants group_id="P5" count="21"/>
                <participants group_id="P6" count="23"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="15"/>
                <participants group_id="P2" count="13"/>
                <participants group_id="P3" count="14"/>
                <participants group_id="P4" count="21"/>
                <participants group_id="P5" count="14"/>
                <participants group_id="P6" count="22"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="7"/>
                <participants group_id="P3" count="7"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="7"/>
                <participants group_id="P6" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Metformin</title>
          <description>Metformin only</description>
        </group>
        <group group_id="B2">
          <title>Metformin + Orlistat</title>
          <description>Metformin&#xD;
Orlistat</description>
        </group>
        <group group_id="B3">
          <title>Metformin + Topiramate</title>
          <description>Metformin&#xD;
Topiramate</description>
        </group>
        <group group_id="B4">
          <title>Topiramate</title>
          <description>Topiramate only</description>
        </group>
        <group group_id="B5">
          <title>Metformin + Topiramate + Orlistat</title>
          <description>Metformin&#xD;
Orlistat&#xD;
Topiramate</description>
        </group>
        <group group_id="B6">
          <title>Placebo</title>
          <description>Placebo: Placebo pills and capsules for metformin, orlistat and topiramate</description>
        </group>
        <group group_id="B7">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="22"/>
            <count group_id="B2" value="20"/>
            <count group_id="B3" value="21"/>
            <count group_id="B4" value="21"/>
            <count group_id="B5" value="21"/>
            <count group_id="B6" value="23"/>
            <count group_id="B7" value="128"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="21"/>
                    <measurement group_id="B2" value="20"/>
                    <measurement group_id="B3" value="21"/>
                    <measurement group_id="B4" value="21"/>
                    <measurement group_id="B5" value="19"/>
                    <measurement group_id="B6" value="23"/>
                    <measurement group_id="B7" value="125"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="2"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="55.04" spread="7.14"/>
                    <measurement group_id="B2" value="55.09" spread="7.46"/>
                    <measurement group_id="B3" value="54.19" spread="6.06"/>
                    <measurement group_id="B4" value="54.3" spread="9.05"/>
                    <measurement group_id="B5" value="56.14" spread="9.05"/>
                    <measurement group_id="B6" value="55.78" spread="7.89"/>
                    <measurement group_id="B7" value="55.13" spread="7.75"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                    <measurement group_id="B2" value="13"/>
                    <measurement group_id="B3" value="14"/>
                    <measurement group_id="B4" value="13"/>
                    <measurement group_id="B5" value="13"/>
                    <measurement group_id="B6" value="16"/>
                    <measurement group_id="B7" value="83"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="7"/>
                    <measurement group_id="B4" value="8"/>
                    <measurement group_id="B5" value="8"/>
                    <measurement group_id="B6" value="7"/>
                    <measurement group_id="B7" value="45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="22"/>
                    <measurement group_id="B2" value="20"/>
                    <measurement group_id="B3" value="21"/>
                    <measurement group_id="B4" value="21"/>
                    <measurement group_id="B5" value="21"/>
                    <measurement group_id="B6" value="23"/>
                    <measurement group_id="B7" value="128"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Weight</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="22"/>
                    <measurement group_id="B2" value="20"/>
                    <measurement group_id="B3" value="21"/>
                    <measurement group_id="B4" value="21"/>
                    <measurement group_id="B5" value="21"/>
                    <measurement group_id="B6" value="23"/>
                    <measurement group_id="B7" value="128"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Weight (% Change From Baseline)</title>
        <description>Weight obtained in the fasting state on a gowned subject.</description>
        <time_frame>6 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Metformin</title>
            <description>Metformin</description>
          </group>
          <group group_id="O2">
            <title>Metformin + Orlistat</title>
            <description>Metformin&#xD;
Orlistat</description>
          </group>
          <group group_id="O3">
            <title>Metformin + Topiramate</title>
            <description>Metformin&#xD;
Topiramate</description>
          </group>
          <group group_id="O4">
            <title>Topiramate</title>
            <description>Topiramate</description>
          </group>
          <group group_id="O5">
            <title>Metformin + Topiramate + Orlistat</title>
            <description>Metformin&#xD;
Orlistat&#xD;
Topiramate</description>
          </group>
          <group group_id="O6">
            <title>Placebo</title>
            <description>Placebo: Placebo pills and capsules for metformin, orlistat and topiramate</description>
          </group>
        </group_list>
        <measure>
          <title>Weight (% Change From Baseline)</title>
          <description>Weight obtained in the fasting state on a gowned subject.</description>
          <units>percentage of weight change</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="22"/>
                <count group_id="O2" value="20"/>
                <count group_id="O3" value="21"/>
                <count group_id="O4" value="21"/>
                <count group_id="O5" value="21"/>
                <count group_id="O6" value="23"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-10.9" lower_limit="-14.4" upper_limit="-7.2"/>
                    <measurement group_id="O2" value="-10.5" lower_limit="-14.0" upper_limit="-6.9"/>
                    <measurement group_id="O3" value="-14.0" lower_limit="-17.3" upper_limit="-10.5"/>
                    <measurement group_id="O4" value="-12.2" lower_limit="-15.6" upper_limit="-8.6"/>
                    <measurement group_id="O5" value="-16.7" lower_limit="-20.3" upper_limit="-13.0"/>
                    <measurement group_id="O6" value="-6.7" lower_limit="-10.5" upper_limit="-2.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Office Systolic Blood Pressure (mmHg Change From Baseline)</title>
        <description>Automated sphygmomanometry while sitting</description>
        <time_frame>6 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Metformin</title>
            <description>Metformin</description>
          </group>
          <group group_id="O2">
            <title>Metformin + Orlistat</title>
            <description>Metformin&#xD;
Orlistat</description>
          </group>
          <group group_id="O3">
            <title>Metformin + Topiramate</title>
            <description>Metformin&#xD;
Topiramate</description>
          </group>
          <group group_id="O4">
            <title>Topiramate</title>
            <description>Topiramate</description>
          </group>
          <group group_id="O5">
            <title>Metformin + Topiramate + Orlistat</title>
            <description>Metformin&#xD;
Orlistat&#xD;
Topiramate</description>
          </group>
          <group group_id="O6">
            <title>Placebo</title>
            <description>Placebo: Placebo pills and capsules for metformin, orlistat and topiramate</description>
          </group>
        </group_list>
        <measure>
          <title>Office Systolic Blood Pressure (mmHg Change From Baseline)</title>
          <description>Automated sphygmomanometry while sitting</description>
          <units>mmHg</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="13"/>
                <count group_id="O3" value="14"/>
                <count group_id="O4" value="14"/>
                <count group_id="O5" value="14"/>
                <count group_id="O6" value="22"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-11.42" lower_limit="-21.10" upper_limit="-1.74"/>
                    <measurement group_id="O2" value="-11.41" lower_limit="-20.88" upper_limit="-1.94"/>
                    <measurement group_id="O3" value="-10.33" lower_limit="-19.52" upper_limit="-1.14"/>
                    <measurement group_id="O4" value="-8.55" lower_limit="-18.53" upper_limit="1.44"/>
                    <measurement group_id="O5" value="-14.47" lower_limit="-24.87" upper_limit="-4.08"/>
                    <measurement group_id="O6" value="-13.26" lower_limit="-23.28" upper_limit="-3.23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Waist (cm Change After 6 Months From Baseline)</title>
        <description>Body fat distribution measured using anthropometry (waist, neck and hip circumferences)</description>
        <time_frame>6 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Metformin</title>
            <description>Metformin only</description>
          </group>
          <group group_id="O2">
            <title>Metformin + Orlistat</title>
            <description>Metformin&#xD;
Orlistat</description>
          </group>
          <group group_id="O3">
            <title>Metformin + Topiramate</title>
            <description>Metformin&#xD;
Topiramate</description>
          </group>
          <group group_id="O4">
            <title>Topiramate</title>
            <description>Topiramate only</description>
          </group>
          <group group_id="O5">
            <title>Metformin + Topiramate + Orlistat</title>
            <description>Metformin&#xD;
Orlistat&#xD;
Topiramate</description>
          </group>
          <group group_id="O6">
            <title>Placebo</title>
            <description>Placebo: Placebo pills and capsules for metformin, orlistat and topiramate</description>
          </group>
        </group_list>
        <measure>
          <title>Waist (cm Change After 6 Months From Baseline)</title>
          <description>Body fat distribution measured using anthropometry (waist, neck and hip circumferences)</description>
          <units>cm change</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="13"/>
                <count group_id="O3" value="14"/>
                <count group_id="O4" value="14"/>
                <count group_id="O5" value="14"/>
                <count group_id="O6" value="22"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-10.62" lower_limit="-20.48" upper_limit="-0.77"/>
                    <measurement group_id="O2" value="-9.04" lower_limit="-18.78" upper_limit="-0.78"/>
                    <measurement group_id="O3" value="-11.65" lower_limit="-21.20" upper_limit="-2.11"/>
                    <measurement group_id="O4" value="-16.63" lower_limit="-26.59" upper_limit="-6.66"/>
                    <measurement group_id="O5" value="-15.76" lower_limit="-26.44" upper_limit="-5.08"/>
                    <measurement group_id="O6" value="-10.78" lower_limit="-20.79" upper_limit="-0.78"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Carotid-femoral Pulse Wave Velocity (PWV)(Change After 6 Months From Baseline)</title>
        <description>Change in carotid-femoral pulse wave velocity (Sphygmocor).</description>
        <time_frame>6 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Metformin</title>
            <description>Metformin</description>
          </group>
          <group group_id="O2">
            <title>Metformin + Orlistat</title>
            <description>Metformin&#xD;
Orlistat</description>
          </group>
          <group group_id="O3">
            <title>Metformin + Topiramate</title>
            <description>Metformin&#xD;
Topiramate</description>
          </group>
          <group group_id="O4">
            <title>Topiramate</title>
            <description>Topiramate</description>
          </group>
          <group group_id="O5">
            <title>Metformin + Topiramate + Orlistat</title>
            <description>Metformin&#xD;
Orlistat&#xD;
Topiramate</description>
          </group>
          <group group_id="O6">
            <title>Placebo</title>
            <description>Placebo: Placebo pills and capsules for metformin, orlistat and topiramate</description>
          </group>
        </group_list>
        <measure>
          <title>Carotid-femoral Pulse Wave Velocity (PWV)(Change After 6 Months From Baseline)</title>
          <description>Change in carotid-femoral pulse wave velocity (Sphygmocor).</description>
          <units>meters/sec</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="13"/>
                <count group_id="O3" value="14"/>
                <count group_id="O4" value="14"/>
                <count group_id="O5" value="14"/>
                <count group_id="O6" value="22"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.09" lower_limit="-2.96" upper_limit="0.78"/>
                    <measurement group_id="O2" value="-1.56" lower_limit="-3.47" upper_limit="0.36"/>
                    <measurement group_id="O3" value="-1.29" lower_limit="-3.13" upper_limit="0.55"/>
                    <measurement group_id="O4" value="-0.24" lower_limit="-2.13" upper_limit="1.64"/>
                    <measurement group_id="O5" value="-0.46" lower_limit="-2.48" upper_limit="1.56"/>
                    <measurement group_id="O6" value="-0.74" lower_limit="-2.98" upper_limit="1.50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Metformin</title>
          <description>Metformin only</description>
        </group>
        <group group_id="E2">
          <title>Metformin + Orlistat</title>
          <description>Metformin&#xD;
Orlistat</description>
        </group>
        <group group_id="E3">
          <title>Metformin + Topiramate</title>
          <description>Metformin&#xD;
Topiramate</description>
        </group>
        <group group_id="E4">
          <title>Topiramate</title>
          <description>Topiramate only</description>
        </group>
        <group group_id="E5">
          <title>Metformin + Topiramate + Orlistat</title>
          <description>Metformin&#xD;
Orlistat&#xD;
Topiramate</description>
        </group>
        <group group_id="E6">
          <title>Placebo</title>
          <description>Placebo: Placebo pills and capsules for metformin, orlistat and topiramate</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="23"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="23"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Gary Pierce, PhD</name_or_title>
      <organization>University of Iowa</organization>
      <phone>13193359487</phone>
      <email>gary-pierce@uiowa.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

